Drug Profile
Research programme: anti-cancer antibodies - Tikcro Technologies/Weizmann Institute of Science
Alternative Names: CTLA-4 antibody - Tikcro Technologies; CTLA-4 Antibody - Tikcro Technologies/Weizmann Institute of ScienceLatest Information Update: 28 Oct 2021
Price :
$50
*
At a glance
- Originator Weizmann Institute of Science
- Developer Tikcro Technologies; Weizmann Institute of Science
- Class Antibodies; Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Cytotoxic T-lymphocyte antigen 4 inhibitors; Programmed cell death-1 receptor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Cancer; Malignant melanoma
Most Recent Events
- 28 Oct 2021 No recent reports of development identified for preclinical development in Cancer in Israel (Parenteral)
- 28 Oct 2021 No recent reports of development identified for preclinical development in Malignant-melanoma in Israel (Parenteral)
- 07 Oct 2019 Preclinical development in Cancer and Malignant melanoma is ongoing in Israel (Parenteral)